Does Rallies show Form 4 insider transactions for ALKS?

Yes. Rallies tracks ALKS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ALKS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALKS. It does not provide personalized investment advice.

ALKS (Alkermes Inc. plc) Stock Analysis - Insider Trades

Alkermes Inc. plc (ALKS) is a publicly traded Healthcare sector company. As of May 21, 2026, ALKS trades at $36.98 with a market cap of $6.20B and a P/E ratio of 40.06. ALKS moved -0.08% today. Year to date, ALKS is +32.07%; over the trailing twelve months it is +16.77%. Its 52-week range spans $25.17 to $39.56. Analyst consensus is strong buy with an average price target of $45.75. Rallies surfaces ALKS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ALKS stock inside the company?

Recent ALKS insider activity includes Gaffin David Joseph sold 2.03K, Hopkinson Craig C. sold 9.00K, Gaffin David Joseph sold 2.03K, Hopkinson Craig C. sold 9.00K, and Gaffin David Joseph sold 2.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ALKS Key Metrics

Key financial metrics for ALKS
Metric	Value
Price	$36.98
Market Cap	$6.20B
P/E Ratio	40.06
EPS	$0.93
Dividend Yield	0.00%
52-Week High	$39.56
52-Week Low	$25.17
Volume	0
Avg Volume	0
Revenue (TTM)	$1.56B
Net Income	$152.72M
Gross Margin	86.63%

Recent ALKS Insider Trades

Gaffin David Joseph sold 2.03K (~$67.53K) on May 4, 2026.
Hopkinson Craig C. sold 9.00K (~$300.56K) on May 1, 2026.
Gaffin David Joseph sold 2.03K (~$70.32K) on Apr 6, 2026.
Hopkinson Craig C. sold 9.00K (~$319.60K) on Apr 1, 2026.
Gaffin David Joseph sold 2.03K (~$60.53K) on Mar 3, 2026.

Latest ALKS News

Alkermes jumps after positive Phase 3 REVITALYZ topline results for LUMRYZ in IH — May 12, 2026
Alkermes falls as investors digest Q1 GAAP loss and Avadel accounting impacts — May 6, 2026
Alkermes Price Target Raised to $50 After Q1 Revenue Beat and $80.3M EBITDA — May 6, 2026
Alkermes climbs after Q1 revenue beat and Avadel-driven 2026 outlook update — May 5, 2026
Alkermes climbs as traders position ahead of May 5 Q1 results, orexin pipeline focus — May 4, 2026

ALKS Analyst Consensus

15 analysts cover ALKS: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $45.75.

Common questions about ALKS

Who is trading ALKS stock inside the company?: Recent ALKS insider activity includes Gaffin David Joseph sold 2.03K, Hopkinson Craig C. sold 9.00K, Gaffin David Joseph sold 2.03K, Hopkinson Craig C. sold 9.00K, and Gaffin David Joseph sold 2.03K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ALKS?: Yes. Rallies tracks ALKS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ALKS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALKS. It does not provide personalized investment advice.